Clinical trials: Adult B Cell ALL
Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL
A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
This is a multicenter, open-label Phase 1 study of acalabrutinib, a selective and irreversible Bruton's tyrosine kinase inhibitor, in Japanese adult patients with advanced B-cell malignancies.
- Conditions
- Part1: Advanced B-cell Malignancies, Part2: r/rCLL and r/rMCL, Part3: Untreated CLL
- Trial name
- NCT03198650
- Testing
- Acalabrutinib, Obinutuzumab
- Where
- 13 sites in Japan
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Lupus Nephritis
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
The purpose of this up to 6-year extension study is the evaluation of the efficacy and safety 1. after study treatment withdrawal in patients with lupus nephritis (LN) who achieved response (complete renal response [CRR] or…
- Trial name
- SIRIUS-LN ext (NCT06711887)
- Testing
- Ianalumab
- Where
- 51 sites in United States, Brazil and 16 more
- Volunteers
- 348 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how well ABBV-453 works adult participants with relapsed/refractory (R/R) untreated CLL/small lymphocytic…
- Trial name
- 453 Ph1 CLL (NCT06291220)
- Testing
- Obinutuzumab, ABBV-453
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 4 people
- Sponsor
- AbbVie
Leukemia, Lymphoma
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive…
- Trial name
- NCT00884286
- Testing
- Aplidin®
- Where
- 12 sites in France, Italy and 4 more
- Volunteers
- 67 people
- Sponsor
- PharmaMar
Chronic Lymphocytic Leukemia
Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia
The primary objective of this study is to evaluate the progression-free survival in participants with previously untreated chronic lymphocytic leukemia (CLL) who would otherwise be suitable for bendamustine and rituximab…
- Trial name
- NCT01980888
- Testing
- Idelalisib, Bendamustine, Rituximab
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 311 people
- Sponsor
- Gilead Sciences
Ependymoma, Ewing Sarcoma
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children…
- Conditions
- Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma
- Trial name
- PIVOT IO 020 (NCT04730349)
- Testing
- Nivolumab, NKTR-214
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people
- Sponsor
- Bristol-Myers Squibb